Clinical Trial Update: A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for MR001 in locally recurrent or metastatic advanced triple-negative breast cancer. The study is a Phase 1/Phase 2 trial and is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• MR001

Snippet

Sponsor: Shenzhen Majory Biotechnology Co., Ltd. | Conditions: Triple-Negative Breast Cancer (TNBC) | Phase 1, Phase 2 | Status: RECRUITING